← Back to Search

Vitamin D Supplement

(CKD) stages III-V and non -CKD patients for Chronic Kidney Disease

N/A
Waitlist Available
Led By Barry M Wall, MD
Research Sponsored by Memphis VA Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
age 18-85 years; CKD stage III or V; serum 25(OH)D level ≤ 30ng/ml, and serum PTH levels > 70 pg/ml within the last 6 months, informed Consent.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights

Study Summary

To determine whether or not chronic kidney disease (CKD), stages III-V and ESRD , is associated with altered vitamin D metabolism related to fibroblast growth factor-23 (FGF-23) stimulation of Cyp24 and whether they have resistance to elevations of 25 Hydroxyvitamin D (25(OH)D3) after cholecalciferol supplementation. To determine if such resistance is related to enhanced catabolism of (25(OH)related to elevated levels of FGF-23.

Eligible Conditions
  • Chronic Kidney Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Kidney Failure, Chronic

Trial Design

1Treatment groups
Experimental Treatment
Group I: (CKD) stages III-V and non -CKD patientsExperimental Treatment1 Intervention
We recruited patients with wide range of eGFR

Find a Location

Who is running the clinical trial?

Memphis VA Medical CenterLead Sponsor
7 Previous Clinical Trials
1,670 Total Patients Enrolled
Barry M Wall, MDPrincipal InvestigatorMemphis , TN ,VAMC
HALA M Alshayeb, MDPrincipal InvestigatorUTHSC, UCH

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Apr 2025